International audienceIn this study we investigate a novel quantitative instrument for the development of intervention strategies for disease modifying drugs in Alzheimer's disease. Our framework is based on the modeling of the spatio-temporal dynamics governing the joint evolution of imaging and clinical biomarkers along the history of the disease, and allows the simulation of the effect of intervention time and drug dosage on the biomarkers' progression. When applied to multi-modal imaging and clinical data from the Alzheimer's Disease Neuroimaging Initiative our method enables to generate hypothetical scenarios of amyloid lowering interventions. The results quantify the crucial role of intervention time, and provide a theoretical justifi...
Alzheimer's disease (AD) is a neurodegenerative condition that leads to dementia, and remains incura...
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American A...
Objective To investigate the influence of heterogeneity in disease progression for detecting treatme...
Alzheimer’s disease (AD) is a neurodegenerativ e disorder characterised by a slow progres- sive dete...
International audienceSimulAD is a computational disease progression model (DPM) originally develope...
International audienceSimulAD is a computational disease progression model (DPM) originally develope...
Objective: To investigate the influence of heterogeneity in disease progression for detecting treatm...
<div><p>Alzheimer’s disease (AD) is a neurodegenerative disorder characterised by a slow progressive...
Abstract Background Despite a tremendous amount of information on the role of amyloid in Alzheimer’s...
Introduction:Alzheimer's disease (AD) is a multisystem and multifactor disease with a long no-sympto...
Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's disease di...
Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's disease di...
Several neuroimaging biomarkers have been identified to diagnose Alzheimer’s disease (AD) since the ...
OBJECTIVE: To investigate the influence of heterogeneity in disease progression for detecting treatm...
In vivo biomarker abnormalities provide measures to monitor therapeutic interventions targeting amyl...
Alzheimer's disease (AD) is a neurodegenerative condition that leads to dementia, and remains incura...
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American A...
Objective To investigate the influence of heterogeneity in disease progression for detecting treatme...
Alzheimer’s disease (AD) is a neurodegenerativ e disorder characterised by a slow progres- sive dete...
International audienceSimulAD is a computational disease progression model (DPM) originally develope...
International audienceSimulAD is a computational disease progression model (DPM) originally develope...
Objective: To investigate the influence of heterogeneity in disease progression for detecting treatm...
<div><p>Alzheimer’s disease (AD) is a neurodegenerative disorder characterised by a slow progressive...
Abstract Background Despite a tremendous amount of information on the role of amyloid in Alzheimer’s...
Introduction:Alzheimer's disease (AD) is a multisystem and multifactor disease with a long no-sympto...
Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's disease di...
Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's disease di...
Several neuroimaging biomarkers have been identified to diagnose Alzheimer’s disease (AD) since the ...
OBJECTIVE: To investigate the influence of heterogeneity in disease progression for detecting treatm...
In vivo biomarker abnormalities provide measures to monitor therapeutic interventions targeting amyl...
Alzheimer's disease (AD) is a neurodegenerative condition that leads to dementia, and remains incura...
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American A...
Objective To investigate the influence of heterogeneity in disease progression for detecting treatme...